Year All2024202320222021202020192018201720162014201320112010 October 15, 2019 Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering September 25, 2019 Rhythm Pharmaceuticals Provides Update on Research and Development Programs September 9, 2019 Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders September 3, 2019 Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September August 7, 2019 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities July 29, 2019 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results July 29, 2019 Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome July 24, 2019 Rhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of Directors July 17, 2019 Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of Obesity June 19, 2019 Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of Directors
September 9, 2019 Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders
August 7, 2019 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
July 29, 2019 Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome
July 24, 2019 Rhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of Directors
July 17, 2019 Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of Obesity
